Future of Shionogi's velneperit hangs in the balance
This article was originally published in Scrip
Executive Summary
Shionogi looks set to make a decision shortly on whether to continue with the Japanese development of its first-in-class obesity drug velneperit (S-2367) following the completion of a second Phase II trial.